Literature DB >> 6370066

Allogeneic marrow transplantation in the treatment of preleukemia.

F R Appelbaum, R Storb, R E Ramberg, H M Shulman, C D Buckner, R A Clift, H J Deeg, A Fefer, J Sanders, P Stewart.   

Abstract

Ten patients with preleukemia and life-threatening pancytopenia were treated with marrow transplantation. In all ten cases allogeneic marrow was successfully engrafted. In three patients prepared for transplantation with cyclophosphamide alone, the abnormal cell clone either persisted or reemerged within 6 months of transplantation. The other seven patients were treated with cyclophosphamide plus total body irradiation before transplantation and six of the seven are alive and well without evidence of disease from 7 to 25 months after transplantation. These results suggest that cyclophosphamide alone before marrow transplantation is incapable of eradicating the abnormal clone. Cyclophosphamide combined with total body irradiation appears more effective, although more time is needed for full evaluation of results. This experience also emphasizes the importance of performing chromosome studies before transplantation for pancytopenic states in order to identify cases of preleukemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370066     DOI: 10.7326/0003-4819-100-5-689

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  Success of allogeneic marrow transplantation for children with severe aplastic anaemia.

Authors:  Lauri M Burroughs; Ann E Woolfrey; Barry E Storer; H Joachim Deeg; Mary E D Flowers; Paul J Martin; Paul A Carpenter; Kris Doney; Frederick R Appelbaum; Jean E Sanders; Rainer Storb
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

Review 2.  The myelodysplastic syndromes.

Authors:  D M Layton; G J Mufti
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-25

Review 3.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

Review 4.  Progress in the therapy of myelodysplastic syndromes.

Authors:  M A Boogaerts
Journal:  Blut       Date:  1989-06

Review 5.  Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.

Authors:  Sergio A Giralt; Mary Horowitz; Daniel Weisdorf; Corey Cutler
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

7.  Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population.

Authors:  Marco Marziali; Antonella Isgrò; Javid Gaziev; Guido Lucarelli
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-26       Impact factor: 2.576

8.  Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia.

Authors:  S J Forman; M R O'Donnell; K G Blume; D I Feinstein
Journal:  Blut       Date:  1987-03

9.  Myelodysplastic syndromes: from neglect to prominence.

Authors:  H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

10.  Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.

Authors:  M A Fridrik; G Wahl; W Herbinger
Journal:  Blut       Date:  1988-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.